Medindia

X

EU Approves Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment

by Kathy Jones on  August 16, 2011 at 8:22 PM Heart Disease News   - G J E 4
The Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment (PRT) has received the European CE Mark approval, Sorin Group has announced.
 EU Approves Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment
EU Approves Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment
Advertisement

The PRT component of the valve is aimed at relieving calcification of the device and increase its durability. A released statement by Sorin said that phospholipids play a key role in the calcification process of biosprotheses.

Advertisement
"The addition of PRT to the Mitroflow bioprosthesis will help mitigate potential calcification and possibly further improve the tissue valve's clinically proven outstanding durability," it added.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All